Edition:
Deutschland

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

68.14USD
18 Oct 2018
Change (% chg)

$-2.09 (-2.98%)
Prev Close
$70.23
Open
$69.66
Day's High
$69.69
Day's Low
$67.47
Volume
2,218,665
Avg. Vol
1,570,872
52-wk High
$74.15
52-wk Low
$53.67

ABT.N

Chart for ABT.N

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Buy/Sell

Sell Hold Buy
1.79 Mean rating from 19 analysts

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

UPDATE 1-Abbott Labs quarterly profit falls on higher tax expense

Oct 17 Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.

Abbott Labs quarterly profit falls 6.6 pct on tax expense

Oct 17 Diversified healthcare company Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.

RPT-EXPLAINER-Why it’s so hard to diagnose Zika

CHICAGO, Oct 17 When a Zika epidemic was at its height in the Americas two years ago, diagnostics makers began working feverishly to create diagnostic tests for a virus that few in the U.S. had heard of.

Photo

Why it's so hard to diagnose Zika

CHICAGO When a Zika epidemic was at its height in the Americas two years ago, diagnostics makers began working feverishly to create diagnostic tests for a virus that few in the U.S. had heard of.

EXPLAINER-Why it’s so hard to diagnose Zika

CHICAGO, Oct 17 When a Zika epidemic was at its height in the Americas two years ago, diagnostics makers began working feverishly to create diagnostic tests for a virus that few in the U.S. had heard of.

Photo

Exclusive: India, U.S. closing in on package deal to remove trade irritants

NEW DELHI Indian farmers and U.S. manufacturers of medical devices could be among the main winners in a trade package under negotiation, as Washington and New Delhi look to remove long-standing irritants to ties, sources familiar with the talks said.

Photo

Exclusive - India, U.S. closing in on package deal to remove trade irritants

NEW DELHI Indian farmers and U.S. manufacturers of medical devices could be among the main winners in a trade package under negotiation, as Washington and New Delhi look to remove long-standing irritants to ties, sources familiar with the talks said.

PRESS DIGEST- British Business - Sept 18

Sept 18 The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.

India bans 328 combination drugs in setback for pharma companies

NEW DELHI, Sept 13 The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.26%
Rohstoffe -0.37%
Industrie -0.20%
Konjunktur abhängige Waren & Dienstleistungen -0.14%
Konjunktur unabhängige Waren & Dienstleistungen -0.08%
Finanzindustrie -0.03%
Pharma -0.08%
Technologie -0.42%
Telekommunikation +0.01%